Telus: A Dividend That Demands a Closer Look
13.06.2026 - 01:11:32 | boerse-global.de
Telus shares are trading at C$16.51, dangerously close to their 52-week low, after shedding more than 8% since the start of the year. On the surface, the quarterly dividend of C$0.4184 per share yields an eye-catching return in a low-yield world. But any income investor tempted by that payout needs to examine the books more carefully.
The ex-dividend date passed on Wednesday, meaning holders as of June 10 will receive the payment on July 2. The board approved the distribution back in May. Yet the mechanics of paying it are becoming increasingly strained. Telus’s payout ratio stands at a staggering 278% — the company is effectively handing out nearly three times what it earns operationally, eating into its own capital base.
Management has acknowledged the strain by hitting pause on dividend growth and trimming the discount on the dividend reinvestment plan. For a company that built its reputation on steadily increasing payouts year after year, that freeze is a loud signal about where priorities now lie: debt reduction, not income growth.
Telus ended the first quarter with a net-debt-to-EBITDA ratio of 3.5 — a level that cramps financial flexibility. The target is to bring that down to 3.3 by the end of 2026 and ultimately to 3.0 a year later. That deleveraging plan is the dominant theme inside the executive suite.
Should investors sell immediately? Or is it worth buying Telus?
The most promising catalyst for a turnaround is Telus Health. The division serves more than 160 million people worldwide and generated C$1.5 billion in operating revenue through the third quarter of 2025. The company has hired TD Securities and Jefferies to advise on a monetization of the unit, though the structure remains uncertain. A clean sale to a single buyer would be the optimal outcome; a drawn-out, piecemeal process would do little to lift the share price.
One bright spot is free cash flow, which jumped 19% in the first quarter to C$583 million. Management has reaffirmed its full-year target of roughly C$2.45 billion, representing a 10% increase. On paper, that supports the dividend. But the small print in the company’s regulatory filings warns that there is no guarantee of a return to dividend growth. That caveat carries extra weight given that net profit plunged 52% in the same quarter, falling to just C$144 million.
The technical picture offers little comfort. The relative strength index sits at 35.8, indicating persistent selling pressure without even reaching oversold territory. With the stock already testing the April low of C$16.18, a break below that level could trigger further downside.
Telus at a turning point? This analysis reveals what investors need to know now.
In short, the dividend is real, but it is coming from a company with declining earnings, a frozen growth trajectory, and a balance sheet that demands repair. For now, investors are being compensated for holding a structurally challenged stock. The real test will be whether Telus Health can deliver a deal big enough to shift the narrative and slash the debt burden. Until that catalyst materializes, the yield is little more than a placeholder.
Ad
Telus Stock: New Analysis - 13 June
Fresh Telus information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
